This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Use of a Loading Dose of Vancomycin in Pediatric Dosing

This study has been terminated.
(PI leaving institution, slow enrollment)
Information provided by (Responsible Party):
Alicia Demirjian, Children's Hospital Boston Identifier:
First received: January 28, 2011
Last updated: March 8, 2012
Last verified: March 2012

Vancomycin is an antibiotic administered to children or adults for many types of infections. While it has been used to treat infections of children for more than 50 years we are still not completely certain about the best dose to use when starting treatment with this medication.

This study is intended to evaluate whether giving a new higher dose of vancomycin for the first dose will help us get to the desired amount in the body more quickly then the usual first dose. Half of the patients would get the new higher dose and the other half of patients will get the typical first dose. Only the first dose is changed and all doses that follow are the same in both groups and are doses typically used for children.

Condition Intervention
Infection Drug: intravenous vancomycin hydrochloride

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Use of a Loading Dose of Intravenous Vancomycin Will Achieve Therapeutic Concentration Earlier Than Conventional Pediatric Dosing: A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Alicia Demirjian, Children's Hospital Boston:

Primary Outcome Measures:
  • proportion of patients whose vancomycin trough reached 15 mcg/mL, 8 hours after the first vancomycin dose, in loading dose group as compared to control group [ Time Frame: 8 hours after the first dose of vancomycin ]

Secondary Outcome Measures:
  • pharmacokinetic parameters for vancomycin in the study population [ Time Frame: within 48 hours after receiving the first dose of vancomycin ]
    mean volume of distribution (to be measured in L) and mean elimination rate constant (to be measured in hour^-1) for vancomycin

Enrollment: 59
Study Start Date: February 2011
Study Completion Date: March 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vancomycin loading dose
Intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
Drug: intravenous vancomycin hydrochloride
see description of study arms
Active Comparator: Control
Intravenous vancomycin 20 mg/kg/dose every 8 hours
Drug: intravenous vancomycin hydrochloride
see description of study arms


Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Receiving care at Children's Hospital Boston
  • Prescribed intravenous vancomycin by their physician

Exclusion Criteria:

  • Weight above 67 kg
  • Pre-existing renal dysfunction (creatinine clearance < 50 ml/min/1.73m2)
  • Known hearing impairment
  • Recent intravenous vancomycin treatment (within 7 days)
  • Undergoing procedure with anticipated moderate-severe blood loss
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01290237

United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children’s Hospital
Principal Investigator: Alicia A Demirjian, MD Boston Children’s Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Alicia Demirjian, Clinical Fellow, Pediatric Infectious Diseases, Children's Hospital Boston Identifier: NCT01290237     History of Changes
Other Study ID Numbers: 10-11-0561
Study First Received: January 28, 2011
Last Updated: March 8, 2012

Keywords provided by Alicia Demirjian, Children's Hospital Boston:
loading dose
Methicillin-Resistant Staphylococcus aureus (MRSA)
Serious infection with Gram positive bacteria

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents processed this record on August 23, 2017